Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Completed
Genzyme, a Sanofi Company
Phase 2
2003-12-01
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C,
and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia,
high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed
following their initial therapy.
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Completed
M.D. Anderson Cancer Center
Phase 2
2003-12-01
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C,
and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia,
high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed
following their initial therapy.
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Terminated
Genzyme, a Sanofi Company
Phase 1
2004-05-01
Primary Objectives:
1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic
Leukemia (CLL).
2. To determine the toxicity profile of clofarabine in CLL.
3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology
profile of clofarabine in CLL.
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Terminated
M.D. Anderson Cancer Center
Phase 1
2004-05-01
Primary Objectives:
1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic
Leukemia (CLL).
2. To determine the toxicity profile of clofarabine in CLL.
3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology
profile of clofarabine in CLL.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
